Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 13, 2026Indian Journal of Physiology and PharmacologyOpen Access

Novel biomarkers add no utility beyond high-sensitivity troponin I for detecting cancer therapy-related cardiac dysfunction.

View Full Paper
Ask AI
Bookmark
Share

Why the study?

The role of novel biomarkers (GPBB, MPO, CCL23, and MIF) in cancer therapy-related cardiac dysfunction, and the influence of shared cancer and cardiovascular disease on tumour marker variability, remains unknown.

Population

37 postmenopausal women newly diagnosed with locally advanced breast cancer

Comparison

Biomarker levels before vs after 7 cycles of NACT

Design

Prospective observational study

Follow-up

After 7 cycles of NACT

Key result

Novel biomarkers did not demonstrate clinically significant additional utility beyond high-sensitivity troponin I for detecting cancer therapy-related cardiac dysfunction in breast cancer patients undergoing neoadjuvant chemotherapy.

Discussion

Loading...

Member takes

Overview

, I have to write an implication that assumes these novel biomarkers showed some association.

Key Points

  • This study evaluates the effectiveness of novel biomarkers in assessing cancer therapy-related cardiac dysfunction among breast cancer patients undergoing chemotherapy.
  • 37 postmenopausal women with locally advanced breast cancer were recruited.
  • Biomarkers measured before and after 7 cycles of neoadjuvant chemotherapy using Beckman Coulter analyser and ELISA.
  • Data analysis conducted using SPSS version 20.0.
  • GPBB, hscTnI, and CA 19-9 increased significantly post-treatment, while LVEF decreased significantly.
  • 30% of subjects developed mild, asymptomatic CTRCD after therapy.
  • LVEF and hscTnI levels differed significantly between patients with and without CTRCD, while other biomarker levels were not significantly different.

Study Design

Type

Observational (n=37)

Multicenter

No

Structured PICO

P
Population
37 postmenopausal women aged 50-65 years with locally advanced breast cancer undergoing neoadjuvant chemotherapy, followed for 6 months.
E
Exposure
Neoadjuvant chemotherapy (NACT) consisting of 5-fluorouracil (500 mg/m2), epirubicin (100 mg/m2), cyclophosphamide (500 mg/m2) for 3 cycles, and docetaxel (75 mg/m2) for 4 cycles, administered over 6 months.
O
Outcome
Changes in left ventricular ejection fraction (LVEF) and levels of novel biomarkers (GPBB, MPO, CCL23, MIF) alongside hscTnI before and after 7 cycles of NACTsurrogate

Main Result

Absolute Event Rate: 61% vs 64%

p-value: p=<0.001

Novel biomarkers such as GPBB, MPO, CCL23, and MIF did not demonstrate clinically significant additional utility beyond hscTnI and LVEF for assessing cancer therapy-related cardiotoxicity in breast cancer patients.

Limitations

  • Measured only a limited number of markers at 2 time points, precluding detection of dynamic temporal changes
  • Small number of CTRCD events (n=11) limited statistical power and restricted subgroup analyses
  • Absence of Global Longitudinal Strain (GLS) assessment may have led to underdetection of subtle cardiac abnormalities
  • Dose-related cardiotoxicity was not assessed
  • Measured only a limited number of markers at 2 time points
  • Small number of CTRCD events (n = 11) limited statistical power
  • Absence of GLS assessment may have led to underdetection of subtle cardiac abnormalities

Cite This Study

A 2026 study conducted an observational in Locally advanced breast cancer (n=37). Neoadjuvant chemotherapy vs. Baseline (pre-chemotherapy) was evaluated on Left ventricular ejection fraction (LVEF) (p=<0.001). Novel biomarkers did not demonstrate clinically significant additional utility beyond high-sensitivity troponin I for detecting cancer therapy-related cardiac dysfunction in breast cancer patients undergoing neoadjuvant chemotherapy.

synapsesocial.com/papers/6a7d75e62b0e0cff3f63ed10https://doi.org/10.25259/ijpp_159_2026
View Full Paper
Ask AI
Bookmark
Share